AGP Executive Report
Last update: 9 hours agoBiopharma Breakthrough: Merck’s TROP2 antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) posted positive Phase 3 results in advanced/recurrent endometrial cancer, hitting overall survival and progression-free survival targets in the TroFuse-005 trial. Health Tech & Research: Microbiotica reported Phase 1b wins for its oral melanoma microbiome co-therapy MB097 with pembrolizumab, with no serious treatment-related adverse events. Sweden in the Spotlight: A self-driving bus trial in Gothenburg hit a tram on its first day with passengers; it braked suddenly, no injuries were reported, and the vehicle was pulled for technical checks. Global Policy: NATO foreign ministers wrapped up talks in Sweden focused on boosting defence spending toward 5% and sustaining support for Ukraine. World Cup Buzz: FIFA confirmed 48 team base camps for the 2026 tournament, with Arab nations set to make a record appearance in the expanded format.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
